| 摘要 |
<p>The present invention relates to the treatment and/or prevention of calcific aortic vascular disease (CAVD) and valve calcification. Particularly, the invention provides a target for intervention in the treatment or prevention of CAVD through the administration of an of inhibitor PLA2G7 expression or Lp-PLA2 enzymatic activity. Also, the invention provides 5 means to treat hypertension related to decreased arterial compliance and vascular calcification. The invention also relates to the use of inhibitors of Lp-PLA2 to prevent structural valve degeneration (SVD) as the major cause of bioprosthetic valve failure leading to bioprostheses (BPs) stenosis or regurgitation.</p> |
